VivoSeq
Immunology

Seasonal Allergic Rhinitis

96

Pipeline Programs↗

15

Active Trials↗

51

Companies Involved↗

Seasonal Allergic Rhinitis is a moderately active landscape with 96 programs across 51 companies. The most active players are Tanabe Pharma Corporation, Sumitomo Pharma Co., Ltd., AstraZeneca. 18 therapies are approved with 29 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

36/100

Mech. Concentration

34/100

Completion Rate

96/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Tanabe Pharma Corporation logo

Tanabe Pharma Corporation

1 program

Phase 1S

Sumitomo Pharma Co., Ltd.

1 program

Phase 1AstraZeneca logo

AstraZeneca

2 programs

Phase 1G

Glenmark Pharmaceuticals Ltd. India

5 programs

Phase 2Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd

2 programs

Phase 2Shionogi logo

Shionogi

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical7

Montelukast Sodium

AstraZeneca

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Ipratropium Bromide

Boehringer Ingelheim

Fluticasone Furoate

GSK

Mometasone Furoate

Novartis

Phase 17

Imatinib

Novartis

MT-2990

Tanabe Pharma Corporation

Ibuprofen

Kenvue Brands

AZD8848

AstraZeneca

DSP-3025

Sumitomo Pharma Co., Ltd.

Phase 235

Oxybutynin

Wim Janssens

GSK256066

GSK

Oxymetazoline

Kenvue Brands

SCH 56592

Merck & Co.

CM310

Keymed Biosciences Co.Ltd

Phase 329

Ciclesonide

Azurity Pharmaceuticals

Bilastine

Menarini International Operations Luxembourg SA

Pseudoephedrine

Kenvue Brands

Resveratrol

National Cancer Institute (NCI)

Omalizumab

Roche

Approved18

Loratadine

Perrigo Company

Cetirizine

Kenvue Brands

Fexofenadine

Chattem

Desloratadine

Organon and Co

Mometasone

Perrigo Company

Analysis

Modality Breakdown

98%

Small molecule

109 of 111 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody1<1%Protein / enzyme1<1%

Small molecule leads; the ring shows all 111 classified programs, each share of the total. Modality classified for 98% of 123 pipeline programs.

Analysis

Trial Status

156

clinical trials

Completed131 · 84%
Not yet recruiting7 · 4%
Recruiting5 · 3%
Unknown status5 · 3%
Active, not recruiting3 · 2%
Terminated3 · 2%
Other2 · 1%

Clinical Trials

Trial Activity

156 trials

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis
Recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT07154342·150 enrolled
A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure
Recruiting·AAlixer Nexgen Therapeutics Limited·Phase 2·NCT07219849·164 enrolled
Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis
Recruiting·SShanghai Mabgeek Biotech.Co.Ltd·Phase 2/3·NCT06846385·160 enrolled
Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
Recruiting·—·Phase 2·NCT06300203·120 enrolled
A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd logoGuangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT07091357·100 enrolled
A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
Active, not recruiting·PPrime Gene Therapeutics Co., Ltd.·Phase 2·NCT06837233·160 enrolled
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
Active, not recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT06315426·240 enrolled
Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis
Active, not recruiting·LLongbio Pharma·Phase 3·NCT07291284·546 enrolled
Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
Not yet recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07398859·300 enrolled
A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
Not yet recruiting·PPrime Gene Therapeutics Co., Ltd.·Phase 3·NCT07146126·600 enrolled
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis
Not yet recruiting·AAkeso·Phase 2·NCT07436234·111 enrolled
A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.
Not yet recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT07199257·144 enrolled
A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)
Not yet recruiting·CChengdu Kangnuoxing Biopharma,Inc.·N/A·NCT07459556·400 enrolled
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
Not yet recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd logoGuangdong Hengrui Pharmaceutical Co., Ltd·Phase 3·NCT07688772·196 enrolled
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Adolescent Patients With Seasonal Allergic Rhinitis Receiving Background Therapy
Not yet recruiting·CChengdu Kangnuoxing Biopharma,Inc.·Phase 3·NCT07678931·136 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)